Skip to main content

Sequenom Narrowly Misses Nasdaq Delisting Warning

NEW YORK, Sept. 20 (GenomeWeb News) - Sequenom narrowly missed receiving a delisting warning from the Nasdaq exchange after is share price closed above $1 last Friday.

 

Shares in the San Diegogenotyping and gene-expression tool company closed at $1.13 Sept. 17. If the stock closed below $1, as it had for the previous 29 trading days, Sequenom would have received a letter from the Nasdaq exchange warning it of its failure to meet minimum trading requirements---the first step in what could have become delisting proceedings.

 

The exchange typically sends its listed companies such letters if their shares trade below $1 for 30 consecutive trading days.

"Certainly we're making every effort to get the price above $1: increasing newsflow, meeting with the investment community to find some new buyers for stock, and fill some of the holes that have been created," a company spokesperson told GenomeWeb News last week. "That's the main plan, at the moment, to build demand for the stock."

 

Before Sept. 17, Sequenom shares last traded on or above $1 on Aug. 5. Had its shares not met the minimum trading criteria, the Nasdaq would have issued a letter giving Sequenom 90 days in which to comply. If the company failed to raise the price above $1 for 90 days after receiving the letter, and maintain a closing price above the threshold for 10 trading days, it would have been downgraded to the Nasdaq small-capitalization market.

 

After that step, Sequenom would have to go through the same process, starting with closing above $1 in a 30-day period. Should it fail the second cycle, the company risks the delisting of its stock to the over-the-counter market.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.